Evidence map›Paper›PMID 31172474›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2019

Guidelines for the Detection of NADPH Oxidases by Immunoblot and RT-qPCR.

Becky A Diebold, S Garrett Wilder, Xavier De Deken, Jennifer L Meitzler, James H Doroshow, James W McCoy, Yerun Zhu, J David Lambeth

Open access · greenAbstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Dynamic regulation of receptor-modulated endothelial NADPH oxidases.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Expression, localization and regulation of NADPH oxidases in pancreatic beta cells.Redox report : communications in free radical research · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Di-Tyrosine Crosslinking andAntioxidants (Basel, Switzerland) · 2021
    Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Becky A DieboldDepartment of Pathology, Emory University, Atlanta, GA, USA. bdiebol@emory.edu.
S Garrett WilderDepartment of Pathology, Emory University, Atlanta, GA, USA.
Xavier De DekenInstitut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire (IRIBHM), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Jennifer L MeitzlerDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
James H DoroshowDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
James W McCoyDepartment of Pathology, Emory University, Atlanta, GA, USA.
Yerun ZhuDepartment of Pathology, Emory University, Atlanta, GA, USA.
J David LambethDepartment of Pathology, Emory University, Atlanta, GA, USA.
Emory University · USCenter for Cancer Research · USNational Cancer Institute · USUniversité Libre de Bruxelles · BE

Funding

NADPH Oxidases as Novel Targets for Cancer TherapyZIABC010677 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI DOROSHOW, JAMES · 2009 to 2025
$15.1M
NADPH Oxidase 1: A Novel Target for Colon Cancer TherapyZ01BC010677 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI DOROSHOW, JAMES HALPERN · 2005 to 2008
$1.1M
Intramural NIH HHS Z01 BC010677
6 · The paper itself

Abstract

The identification of NADPH oxidase (NOX) isoforms in tissues is essential for interpreting experiments and for next step decisions regarding cell lines, animal models, and targeted drug design. Two basic methods, immunoblotting and reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR), are important to monitor NOX protein and messenger RNA (mRNA) levels, respectively, for a range of investigations from understanding cell signaling events to judging NOX inhibitor efficacies. For many other genes that are expressed in high abundance, these methods may seem rather simple. However, detecting the low expression levels of endogenous NOX/DUOX is difficult and can be frustrating, so some guidelines would be helpful to those who are facing difficulties. One reason why detection is so difficult is the limited availability of vetted NOX/DUOX antibodies. Many of the commercial antibodies do not perform well in our hands, and dependable antibodies, often generated by academic laboratories, are in limited supply. Another problem is the growing trend in the NOX literature to omit end-user validation of antibodies by not providing appropriate positive and negative controls. With regard to NOX mRNA levels, knockdown of NOX/DUOX has been reported in cell lines with very low endogenous expression (C

Indexed as

ImmunoblottingReverse Transcriptase Polymerase Chain ReactionAnimalsCell LineEnzyme ActivationGuidelines as TopicHumansIsoenzymesKineticsNADPH OxidasesIsoenzymesNADPH OxidasesImmunoblotNOX antibodiesNOX qPCR primers

Identifiers

PMID31172474
PMCPMC8132109
OpenAlexW2963619366

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.